Breast biopsy helps confirm what a suspicious breast change might be. In the U.S., about 1.6 million biopsies are performed each year, and many women need more than one exam over their lifetime. Learn how core needle, ultrasound-guided, stereotactic, and vacuum-assisted techniques compare for accuracy, side effects like pain, bleeding, and infection, and what benign versus malignant results can mean for follow-up and future risk.
Key Takeaways
- Hematoma formation in 2-11% of biopsies.
- Infection risk post-biopsy is 0.1-1%.
- Pain reported in 20-50% of patients post-procedure.
- Sensitivity of CNB is 97%.
- Specificity of ultrasound-guided biopsy is 98%.
- False-negative rate for CNB is 1-2%.
- Approximately 1.6 million breast biopsies are performed annually in the United States.
- In 2020, about 42,170 new cases of female breast cancer in situ were diagnosed in the US.
- Breast biopsies account for over 1.5% of all Medicare procedures.
- 5-year cancer detection rate post-biopsy 15% in benign cases.
- Benign biopsy patients have 0.5% annual cancer risk.
- 70% of malignant biopsies lead to lumpectomy.
- 60% of biopsies are core needle biopsies (CNB).
- Ultrasound-guided biopsies comprise 50% of all breast biopsies.
- Stereotactic biopsy used in 25% of non-palpable lesions.
Most breast biopsies are accurate and common, with low serious complications but frequent mild pain.
Related reading
01 · Category
Complications16 stats
01
Hematoma formation in 2-11% of biopsies.
02
Infection risk post-biopsy is 0.1-1%.
03
Pain reported in 20-50% of patients post-procedure.
04
Bleeding complications in 1-3% requiring intervention.
05
Pneumothorax rare, <0.5% in lateral approaches.
06
Allergic reaction to anesthesia 0.5%.
07
Clip migration occurs in 10-20% of cases.
08
Vasovagal reaction in 1-5% during procedure.
09
Seroma formation 5-10%.
10
Skin necrosis <1% with VAB.
11
Rebiopsy rate due to technical failure 2-5%.
12
Neuralgia post-procedure 1-2%.
13
Pseudoaneurysm rare, 0.1%.
14
Antibiotic prophylaxis reduces infection by 50%.
15
MRI biopsy pain higher, 30% vs 15% ultrasound.
16
90% of complications resolve without treatment.
Interpretation
Complications Interpretation
Under the complications angle, most breast biopsy issues are relatively uncommon and self-limited, with hematomas occurring in 2–11% and bleeding needing intervention in only 1–3%, while infections remain low at 0.1–1% and even rare events like pneumothorax are under 0.5% in lateral approaches.
02 · Category
Diagnostic Metrics16 stats
01
Sensitivity of CNB is 97%.
02
Specificity of ultrasound-guided biopsy is 98%.
03
False-negative rate for CNB is 1-2%.
04
Positive predictive value (PPV) for suspicious mammograms is 30%.
05
FNA sensitivity 85-95%, specificity 90-100%.
06
MRI biopsy sensitivity 89-98%.
07
Underestimation rate of DCIS on CNB is 20-30%.
08
Stereotactic CNB accuracy 95-99%.
09
Sampling error in FNA is 10-15%.
10
Concordance rate between biopsy and excision 90%.
11
NPV of negative CNB in high-suspicion lesions 95%.
12
Upgrade rate from atypical ductal hyperplasia to cancer 20%.
13
BI-RADS 4 lesions have 2-95% malignancy risk.
14
Radial scar underestimation 30-40%.
15
Lobular neoplasia upgrade rate 15-30%.
16
CNB false-positive rate <1%.
Interpretation
Diagnostic Metrics Interpretation
In diagnostic metrics for breast biopsy, CNB delivers very high performance with 97% sensitivity and 98% specificity, reflected in a low 1 to 2% false-negative rate, underscoring strong accuracy compared with other approaches.
03 · Category
Incidence And Prevalence20 stats
01
Approximately 1.6 million breast biopsies are performed annually in the United States.
02
In 2020, about 42,170 new cases of female breast cancer in situ were diagnosed in the US.
03
Breast biopsies account for over 1.5% of all Medicare procedures.
04
20-30% of women undergo at least one breast biopsy in their lifetime.
05
In Europe, around 500,000 breast biopsies are conducted yearly.
06
US biopsy rate rose from 20 to 34 per 1,000 women between 2000-2010.
07
80% of breast biopsies in the US are image-guided.
08
Globally, breast cancer incidence is 2.3 million new cases per year, leading to biopsies.
09
In China, breast biopsy volume increased 15% annually from 2010-2020.
10
African American women have a 10% higher biopsy rate than white women.
11
25% of mammogram callbacks result in biopsy recommendation.
12
UK performs 150,000 breast biopsies yearly.
13
Biopsy rates doubled in women under 50 from 1990-2010.
14
15% of biopsies are done on high-risk patients with genetic mutations.
15
Canada reports 100,000+ breast biopsies annually.
16
Biopsy utilization increased 50% post-mammography screening programs.
17
40% of biopsies in Asia are ultrasound-guided due to dense breasts.
18
Australia sees 80,000 biopsies per year.
19
Post-COVID, biopsy delays affected 20% of cases.
20
10% annual increase in stereotactic biopsies worldwide.
Interpretation
Incidence And Prevalence Interpretation
Across the Incidence and Prevalence landscape, the US saw breast biopsy rates climb from 20 to 34 per 1,000 women between 2000 and 2010, alongside an estimated 20 to 30 percent of women needing at least one biopsy in their lifetime.
More related reading
04 · Category
Outcomes14 stats
01
5-year cancer detection rate post-biopsy 15% in benign cases.
02
Benign biopsy patients have 0.5% annual cancer risk.
03
70% of malignant biopsies lead to lumpectomy.
04
Survival rate improves 30% with early biopsy detection.
05
Discordant benign results prompt excision in 10%.
06
High-risk lesions excised show upgrade in 25%.
07
Patient satisfaction 95% with minimally invasive biopsy.
08
Interval cancer rate reduced 40% post-biopsy surveillance.
09
85% of DCIS detected via biopsy is non-invasive.
10
Recurrence-free survival 98% for stage 0 post-biopsy.
11
Psychological distress peaks at 1 month post-biopsy, resolves 80%.
12
Cost-effectiveness: CNB saves $1,000vs open biopsy.
13
92% avoid surgery after benign CNB.
14
Long-term follow-up shows 99% accuracy in negative CNB.
Interpretation
Outcomes Interpretation
From an outcomes perspective, benign biopsy patients still face a low but real 0.5% annual cancer risk and only 15% show 5-year cancer detection, yet a timely biopsy that leads to early detection can improve survival by 30%.
05 · Category
Procedure Statistics20 stats
01
60% of biopsies are core needle biopsies (CNB).
02
Ultrasound-guided biopsies comprise 50% of all breast biopsies.
03
Stereotactic biopsy used in 25% of non-palpable lesions.
04
Vacuum-assisted biopsy (VAB) performed in 30% of cases.
05
Fine needle aspiration (FNA) accounts for 10% of biopsies.
06
MRI-guided biopsies make up 5% but increasing.
07
Average procedure time for CNB is 15-20 minutes.
08
70% of biopsies are outpatient procedures.
09
Local anesthesia used in 95% of percutaneous biopsies.
10
Surgical excisional biopsies now <10% due to minimally invasive shift.
11
40% of biopsies use 14-gauge needles.
12
Tomosynthesis-guided biopsies rose 200% since 2011.
13
85% of procedures done by radiologists.
14
Dual-probe VAB used in 15% for larger lesions.
15
Average cost of CNB is $1,500-$2,500 in US.
16
20-gauge needles preferred for FNA in 60% cases.
17
Spring-loaded guns used in 90% of CNB.
18
Patient positioning: prone for 10%, upright for 90% stereotactic.
19
Compression time averages 2 minutes pre-biopsy.
20
14g vs 16g needles: 14g yields 20% more tissue.
Interpretation
Procedure Statistics Interpretation
In procedure statistics, core needle biopsy is the dominant approach at 60% while imaging guidance is especially prevalent with ultrasound-guided biopsies at 50% and MRI-guided biopsies at 5% yet rising.
report visual · Breakdown
Key Post-Biopsy Complications
Common short-term complications and rates after breast biopsy.
1%
Skin necrosis <1% with VAB.
99%
Long-term follow-up shows 99% accuracy in negative CNB.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lars Eriksen. (2026, February 13). Breast Biopsy Statistics. Gitnux. https://gitnux.org/breast-biopsy-statistics
MLA
Lars Eriksen. "Breast Biopsy Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-biopsy-statistics.
Chicago
Lars Eriksen. 2026. "Breast Biopsy Statistics." Gitnux. https://gitnux.org/breast-biopsy-statistics.
Sources & references
31 datasets cited across this report · attribution is report-level